Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond

摘要: For patients with advanced cancers there has been a concerted effort to transition from generic treatment paradigm one based on tumor-specific biologic, and patient-specific clinical characteristics. This approach, known as precision therapy made possible owing widespread availability reduction in the cost of cutting-edge technologies that are used study genomic, proteomic, metabolic attributes individual tumors. review traces evolution for lung cancer identification molecular subsets disease development approval tyrosine kinase, well immune checkpoint inhibitors therapy. Challenges era including emergence acquired resistance, untargetable mutations, effect trial design discussed. We conclude by highlighting newer applications concept